Patients with high grade gliomas endure devastating disease processes with high symptomatic burden and frequency of progression and recurrence. The aim of this study is to assess the feasibility to detect and track symptom transitions preceding tumor recurrences using connected digital tools to develop a sensor map of symptom progression. Our ultimate goal is to identify digital biomarkers that could eventually help provide methods for screening individuals as an early detection system for tumor recurrence.

Description of the study:

The Help Enable Real-Time Observations (HERO) - Central Nervous System (CNS) tumor detection study is a Mark Foundation funded prospective cohort feasibility study. Patients with high grade gliomas will be recruited from John Hopkins Medical Center. We plan to collect semi-continuous passive and active measurements (when possible before surgery/radiation therapy/chemotherapy) using smartphone applications to collect and transmit data, alongside a smart ring and a smart wristwatch. We plan to retrospectively analyze relative changes of multi-modal data streams among those who did and did not demonstrate new tumor growth.

Size and Timing:
This study is due to launch in Q2 2021 and will follow 60- 80 patients for 6-12 months.

Mark Foundation

Clinical Partner(s):
John Hopkins Medical Center

Coalition and Collaboration Partners:
Evidation, Vector Institute, and the Institute for Systems Biology (proteomic analyses in accompanying study)